LUNGevity Foundation Launches Inhale for Life: Clinical Trials Public Service Video and Social Media Campaign During Lung Cancer Awareness Month

On November 14, 2019 LUNGevity, the nation’s leading lung cancer-focused nonprofit organization, reported that features the stories of lung cancer survivors and their families in its Inhale for Life: Clinical Trials public service campaign launched during Lung Cancer Awareness Month (Press release, LUNGevity Foundation, NOV 14, 2019, View Source [SID1234551330]). This powerful social media video series aims to educate and encourage people living with lung cancer to explore treatment options that may be available to them through clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Experience the interactive Multichannel News Release here: View Source

Given the rapidly evolving therapeutic and diagnostic options available in lung cancer, clinical trials can provide a potential treatment option for lung cancer patients today. Trials are a critical resource for the discovery of new treatment methods for cancer, yet many people are unaware of them and the potential benefits they may receive by participating. Further, the treatment options available today would not have been possible without clinical trials and the patients who participated in them. Inhale for Life: Clinical Trials campaign stresses the importance of clinical trials and is designed to spread awareness to lung cancer patients and their families.

"The field of lung cancer research and patient care is accelerating at an exciting and truly remarkable pace," says Andrea Ferris, President and CEO of LUNGevity Foundation. "More people live well with lung cancer today than ever before, and that is very good news, but, with more than 228,000 people expected to be diagnosed this year, we still have a long way to go. Our goal with Inhale for Life: Clinical Trials is to reach as many people as possible diagnosed with lung cancer and educate them about the importance and benefits of clinical trials."

Lung cancer is the second most commonly diagnosed cancer in the world, with more than 1.8 million new cases diagnosed every year. Nearly 65% of all new diagnoses are nonsmokers. Today, through advancements in research, many lung cancer patients are living longer and better lives. Yet, the disease often goes undetected until late stages when it is harder to treat. LUNGevity is proud of its impact on improving outcomes for lung cancer patients through a better understanding of diagnosis, treatment, and quality of life, as well as through driving research and policy reforms.

Videos in the Inhale for Life: Clinical Trials series stress the importance of clinical trials and their potential role in the clinical care of patients. Thanks to the medical advances available through clinical trials, the lung cancer survivors featured are able to continue to live and thrive, from working high-level corporate jobs to celebrating milestones in the lives of their children and grandchildren; their lives kindles new hope for progress in lung cancer treatment and their participation helps demonstrate safety and efficacy of new drugs for future patients. While clinical trials may not be appropriate for all patients, the videos encourage viewers to talk to their doctor to see if a clinical trial could be right for them.

LUNGevity strives to ensure that all people diagnosed with lung cancer have access to optimal care and support to help them live their best lives possible. Because clinical trials can at times be the best treatment options available for some patients, LUNGevity advocates for access to trials so that all patients who are eligible can participate. LUNGevity provides support services to provide information to those considering a clinical trial, such as Clinical Trial Ambassadors, a peer-to-peer trial buddy matching service that pairs lung cancer clinical trial participants with someone who is considering participation, to provide encouragement and offer experiential insights.

A Clinical Trial Finder helps people find available clinical trials by type of lung cancer and geographic location. LUNGevity’s Scientific and Clinical Roundtable convenes multi-stakeholder participants, including regulators, industry leaders, clinicians and patients, and focuses on defining and then achieving ideal patient-centric, efficient, clinical trials and therapy development paradigms for lung cancer.

The Inhale for Life: Clinical Trials campaign is supported in part by grants from Amgen Oncology, Bristol-Myers Squibb, EMD Serono, and Genentech. The campaign can be seen at View Source

ThermoGenesis Holdings To Postpone Third Quarter 2019 Earnings Release And Conference Call Until Tuesday November 19, 2019

On November 14, 2019 ThermoGenesis Holdings, Inc. (Nasdaq: THMO) formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, reported it will delay its third quarter ended September 30, 2019 earnings release and subsequent earnings conference call, previously scheduled for today to Tuesday, November 19, 2019 (Press release, Thermogenesis, NOV 14, 2019, View Source [SID1234551327]). A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. The company will file a Form 12B-25 with the Securities Exchange Commission to extend its filing deadline for five calendar days until Tuesday, November 19, 2019 for its 10-Q third quarter report. As long as the company files the third quarter 10-Q within the five-day grace period, the report is deemed to have been filed timely by the Securities and Exchange Commission. The delay in filing is to allow for additional time to address complex accounting issues, including the completion of a third-party valuation related to the convertible note issued by the company in the quarter ended September 30, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: View Source

A replay of the call will be available until December 10 and can be accessed by dialing 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 1-855-669-9658 (Canada) and referencing access code 10136101. The webcast will be available for three months.

Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference

On November 14, 2019 Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, reported that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled "Building Momentum for Patients with Myelofibrosis" at the Jefferies 2019 London Healthcare Conference in London, United Kingdom (Press release, Sierra Oncology, NOV 14, 2019, View Source [SID1234551326]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation is scheduled for 6:00 p.m. GMT on Wednesday, November 20, 2019. A live audio webcast and archive of the presentation will be accessible through www.sierraoncology.com.

Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences

On November 14, 2019 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company will webcast its corporate presentations at three upcoming investor conferences (Press release, Jazz Pharmaceuticals, NOV 14, 2019, View Source [SID1234551325]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2019 London Healthcare Conference in London, UK on Thursday, November 21, 2019 at 10:40 a.m. GMT / 5:40 a.m. EST. Daniel Swisher, president and chief operating officer, will provide an overview of the company and a business and financial update.
Piper Jaffray 31st Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2019 at 8:00 a.m. EST / 1:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
Evercore ISI 2nd Annual HealthCONx Conference in Boston, MA on Wednesday, December 4, 2019 at 8:00 a.m. EST / 1:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of each presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of each webcast will be available for at least one week following each presentation on the Investors section of the company’s website at www.jazzpharmaceuticals.com.

Kindred Biosciences to Participate in Stifel Healthcare Conference and Jefferies London Healthcare Conference

On November 14, 2019 Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, reported that it will participate in the Stifel Healthcare Conference on November 19 in New York City and Jefferies London Healthcare Conference on November 21 (Press release, Kindred Healthcare, NOV 14, 2019, View Source [SID1234551324]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Richard Chin, Chief Executive Officer, will present and be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio’s first product, study results from key therapeutic programs in development, and upcoming milestones.

Conference Details:

Stifel Healthcare Conference

Date: Tuesday, November 19, 2019

Presentation time: 10:20-10:50a.m. ET in Kennedy

Location: Lotte New York Palace Hotel

Webcast URL: Click here

Jefferies London Healthcare Conference

Date: Thursday, November 21, 2019

Location: Waldorf Hilton, London

An archived version of the above webcast will be available for 30 days on the KindredBio website.